Bristol Opens A Phase III Door Into Gamma Secretase As Lilly Closes Another
Whether Bristol-Myers Squibb Co. and others can succeed at bringing a gamma secretase inhibitor to market for the treatment of Alzheimer's disease is far from certain.
You may also be interested in...
One way or another, it is an important time in the Alzheimer’s disease space. Two potential disease altering therapies are set to divulge Phase III results that will answer important questions about the course of the illness, whether they are successful or not, and a promising cognition booster may get the Phase II readout it needs to head into a pivotal trial.
Lilly is relying heavily on biomarkers to help its Alzheimer’s disease-modifying drug solanezumab progress, executives tell a crowd of analysts at JP Morgan,
Lilly is relying heavily on biomarkers to help its Alzheimer’s disease-modifying drug solanezumab progress, executives tell a crowd of analysts at JP Morgan. Though the project is high risk, Lechleiter pointed to the company’s full pipeline and success of diabetes portfolio as signs of Lilly’s momentum.